Merck's lambrolizumab wins breakthrough status for melanoma

04/25/2013 | Fox Business

The FDA granted breakthrough therapy status to Merck & Co.'s experimental antibody drug lambrolizumab as a treatment for advanced melanoma. Lambrolizumab, which targets the programmed death receptor, is also being evaluated as a treatment for nonsmall-cell lung cancer.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA